GlassScriptPhysician profile
Stephen M Ashe
NPI 1952300634
$5,107.28
in general payments reported to CMS, 2019-2025
40 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $925 · 2021: $1,269 · 2022: $753 · 2023: $617 · 2024: $740 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,738.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $672.47 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $630.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $587.86 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $470.57 | 2019-2024 | Xifaxan |
| Amarin Pharma, INC. | $452.03 | 2019-2021 | |
| Lilly USA, LLC | $420.69 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $337.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $253.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.10 | 2020-2025 | Jardiance, Tradjenta |
| Amgen INC. | $96.76 | 2020-2024 | Repatha, Otezla |
| Genentech USA, INC. | $80.58 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $67.78 | 2022 | |
| Eisai INC. | $65.51 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.42 | 2021 | |
| Nestle Healthcare Nutrition INC. | $59.77 | 2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ashe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.